Compare Dominion Energy Inc (D) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dominion Energy Inc vs Inovio Pharmaceuticals Inc — how do they compare? Dominion Energy Inc trades at $71.4 (market cap $62.71B), while Inovio Pharmaceuticals Inc trades at $1.19 (market cap $95.85M). The key difference: Dominion Energy Inc is far larger — about 654.3× Inovio Pharmaceuticals Inc's market cap, and Dominion Energy Inc pays a 3.74% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| D | INO | |
|---|---|---|
Market Cap | $62.71B | $95.85M |
Sector | Utilities | Health |
52-Week High | $71.32 | $2.87 |
52-Week Low | $56.55 | $1.05 |
Enterprise Value | $115.11B | $66.86M |
Dividend Yield | 3.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dominion Energy (D) trades at $70.8, up 1.03% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $70.14. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.95, and maintains a solid net income margin of 16.93%. Recent news highlights a proposed $66.8 billion acquisition by NextEra Energy, positioning D at the center of AI-driven power demand trends.
The outlook for D is mixed; upside potential exists from rising electricity demand and strategic acquisitions, but risks include regulatory scrutiny of the NextEra deal and high debt levels. Analysts are cautious, with 59% holding a neutral rating, reflecting balanced opportunities and headwinds for investors.
INO trades at $1.16, down 1.69% on the day, with a bearish technical outlook from moving averages. The company shows minimal revenue of $65.34K in 2025 and a net loss of $84.95M, resulting in a negative net margin of 130,000%. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, alongside shareholder litigation concerns.
The investment case hinges on the binary FDA decision for INO-3107, offering high upside potential but significant risk. Analyst consensus is moderately positive with 53% buy ratings, yet fundamental weaknesses and negative cash flows pose substantial risks for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
